Back to Hematology
Hematologyv2016Evidence-Based

WHO Diagnostic Criteria for Polycythemia Vera (2016)

World Health Organization 2016 diagnostic criteria for polycythemia vera. Requires 3 major criteria OR 2 major criteria + 1 minor criterion for diagnosis. Designed to detect masked polycythemia vera cases missed by previous 2008 criteria.

Clinical Input Parameters

g/dL
Range: 5 — 25 g/dL
%
Range: 10 — 80 %
Clinical Assessment
Awaiting Parameters
diagnosis status
—categorical
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The WHO Diagnostic Criteria for Polycythemia Vera (2016) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Diagnosis requires meeting 3 major criteria OR 2 major criteria + 1 minor criterion. Major criteria: (1) Hemoglobin >16.5 g/dL (men) or >16.0 g/dL (women) OR Hematocrit >49% (men) or >48% (women) OR elevated red cell mass >25% above normal; (2) Bone marrow hypercellularity with trilineage growth; (3) JAK2V617F or JAK2 exon 12 mutation. Minor criterion: Subnormal serum erythropoietin level.

Clinical Pearls & Practice Notes

  • The 2016 WHO criteria lowered hemoglobin thresholds from the 2008 criteria to detect masked polycythemia vera cases
  • Hematocrit thresholds were newly introduced in 2016 as alternative to hemoglobin levels
  • Bone marrow morphology was elevated from minor to major criterion in 2016
  • JAK2V617F mutation is found in ~95% of PV patients; JAK2 exon 12 mutations in ~3% of cases
  • Subnormal EPO level helps distinguish PV from secondary polycythemia
  • These criteria are specifically for polycythemia vera and not other myeloproliferative neoplasms
  • Bone marrow biopsy is essential for diagnosis and should show age-adjusted hypercellularity
  • Alternative erythroid mass measurement may be used when Hgb/Hct are borderline

Evidence & Literature Citations

  1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi: 10.1182/blood-2016-03-643544
  2. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. doi: 10.1038/s41408-018-0054-y
  3. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(12):1599-1613. doi: 10.1002/ajh.26008
  4. Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016;172(5):786-793. doi: 10.1111/bjh.13884

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.